Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

AMA State Advocacy Roundtable Addresses Pressing Policy Challenges

From the College  |  September 5, 2025

The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.

Filed under:Legislation & Advocacy Tagged with:AMAstate legislation

Celebrating Interdisciplinary Collaboration: Pathways to Success

Teresa J. Brady, PhD, MACR, Basia Belza, PhD, RN, FAAN, FGSA, Kimberly Kimpton, PT, MACR, & Marian T. Hannan, DSc, MPH, MACR  |  September 2, 2025

Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.

Filed under:From the CollegePractice SupportWorkforce Tagged with:advanced practice providersAssociation of Rheumatology Professionals (ARP)Collaboration Initiativeshealth professionalsHistoryinterdisciplinaryWorkforce

Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists

Vanessa Caceres  |  August 26, 2025

Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.

Filed under:Biologics/DMARDsConditionsDrug UpdatesResearch RheumSjögren’s Disease Tagged with:autologous serum tearsCare TeamcollaborationcyclosporineDry eyeEye diseaseHYDROXYCHLOROQUINElifitegrastocularOphthalmologistReferralsicca syndromeSjögren’s Disease supplement

Dazodalibep for Sjögren’s Disease

Michele B. Kaufman, PharmD, BCGP  |  August 26, 2025

St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSjögren’s Disease Tagged with:adverse eventsclinical trialsdazodalibepDry eyefatiguePainSjögren’s Disease supplement

New FDA Label Requirements for Opioids

Michele B. Kaufman, PharmD, BCGP  |  August 26, 2025

After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.

Filed under:AnalgesicsDrug Updates Tagged with:Chronic painFDAopioidU.S. Food and Drug Administration (FDA)

Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease

Michele B. Kaufman, PharmD, BCGP  |  August 26, 2025

A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsSjögren’s Disease Tagged with:efgartigimod alfa-fcabEULAR 2025Sjogren's

At Summer Meeting, Insurance Legislators Discuss Policies Impacting Rheumatology

From the College  |  August 23, 2025

The National Council of Insurance Legislators (NCOIL) 2025 Summer Meeting, held July 16–19 in Chicago, Ill., included discussion of several policy issues relevant to rheumatology.

Filed under:InsuranceLegislation & AdvocacyMeeting Reports Tagged with:state legislation

Case Report: Pulmonary Artery Stenosis Secondary to Granulomatosis with Polyangiitis

Sambhawana Bhandari, MD, & Colin Diffie, MD  |  August 7, 2025

This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitiscase reportFellows Forumgranulomatosis with polyangiitislarge-vessel vasculitisPulmonary Artery StenosisPulmonary Artery Stentingpulmonary hypertension

Emerging Therapies for Antiphospholipid Syndrome, an Antibody-Mediated Disease

Katie Robinson  |  August 6, 2025

A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.

Filed under:Biologics/DMARDsConditionsDrug UpdatesGuidanceOther Rheumatic ConditionsResearch Rheum Tagged with:AntibodiesanticoagulantAntiphospholipid syndromeautoantibodiesB cellsCAR-T cell therapyHYDROXYCHLOROQUINEImmunology Insightslupus anticoagulantPathogenesisrituximabthrombosiswarfarin

Editor's Pick

Understanding Immunologic Complications of Measles

Ruth Jessen Hickman, MD  |  August 6, 2025

As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGuidance Tagged with:BiologicsImmunityimmunocompromisedimmunosuppressioninfectious diseaselive vaccineMeaslesMMRoutbreakspublic healthvaccinationvaccine hesitancy

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences